This is an old revision of the document!
Jaahnavi Dave
Jaahnavi Dave is a PhD student based in Ottawa, Ontario. She works in the cancer immunotherapy program at the Ottawa Hospital Research Institute.
History
As an undergraduate student at McGill University, Dave participated in BioCanRx's 2018 Summer Studentship Program. She worked in the laboratory of Denis Claude Roy at the Université de Montréal.1) She conducted research on targeted cell therapy funded by BioCanRx.2)
Dave won the first place prize for best oral presentation at the 2019 Ontario-Quebec Undergraduate Immunology Conference.3)
Activities
Research
Dave has published research funded by a Fonds de Recherche de Québec - Santé Schan Ontario Graduate Scholarship.4)
She also published a paper funded by Mitacs, Ottawa Hospital Foundation, the Thistledown Foundation, the Terry Fox Research Institute, and the Canadian Cancer Society on TOH-Vac1, a COVID-19 vaccine candidate based on the original smallpox vaccine.5)
External links
1)
Introducing the winners of BioCanRx’s 2018 Summer Studentships. (2018, April 26). BioCanRx. https://web.archive.org/web/20230316080713/https://biocanrx.com/introducing-winners-biocanrx-2018-summer-studentships
2)
BioCanRx Summer Students Tell All. (2018, September 21). BioCanRx. https://web.archive.org/web/20220429044210/https://biocanrx.com/biocanrx-summer-students-tell
3)
Jaahnavi Dave - LinkedIn Profile. (2023, March 19). Internet Archive; LinkedIn. https://archive.org/details/jaahnavi-dave-linkedin-profile
4)
Surendran, A., Jamalkhah, M., Poutou, J., Birtch, R., Lawson, C., Dave, J., Crupi, M. J. F., Mayer, J., Taylor, V., Petryk, J., de Souza, C. T., Moodie, N., Billingsley, J. L., Austin, B., Cormack, N., Blamey, N., Rezaei, R., McCloskey, C. W., Fekete, E. E. F., & Birdi, H. K. (2023). Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1099459
5)
Boulton, S., Poutou, J., Martin, N. T., Azad, T., Singaravelu, R., Crupi, M. J. F., Jamieson, T., He, X., Marius, R., Petryk, J., Tanese de Souza, C., Austin, B., Taha, Z., Whelan, J., Khan, S. T., Pelin, A., Rezaei, R., Surendran, A., Tucker, S., & Fekete, E. E. F. (2022). Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. Molecular Therapy, 30(5), 1885–1896. https://doi.org/10.1016/j.ymthe.2021.10.008